

## MAJOR ARTICLE

# Novel Genotyping Tools for Investigating Transmission Dynamics of *Plasmodium falciparum*

Rahel Wampfler,<sup>1,2</sup> Lincoln Timinao,<sup>1,2,3</sup> Hans-Peter Beck,<sup>1,2</sup> Issiaka Soulama,<sup>4</sup> Alfred B. Tiono,<sup>4</sup> Peter Siba,<sup>3</sup> Ivo Mueller,<sup>5,6</sup> and Ingrid Felger<sup>1,2</sup>

<sup>1</sup>Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, <sup>2</sup>University of Basel, Switzerland; <sup>3</sup>Papua New Guinea Institute of Medical Research, Goroka, Eastern Highland Province; <sup>4</sup>Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; <sup>5</sup>Walter and Eliza Hall Institute, Parkville, Victoria, Australia; and <sup>6</sup>Barcelona Centre for International Health Research (CRESIB), Spain

**Background.** Differentiation between gametocyte-producing *Plasmodium falciparum* clones depends on both high levels of stage-specific transcripts and high genetic diversity of the selected genotyping marker obtained by a high-resolution typing method. By analyzing consecutive samples of one host, the contribution of each infecting clone to transmission and the dynamics of gametocyte production in multiclonal infections can be studied.

**Methods.** We have evaluated capillary electrophoresis based differentiation of 6 length-polymorphic gametocyte genes. RNA and DNA of 25 µL whole blood from 46 individuals from Burkina Faso were simultaneously genotyped.

**Results.** Highest discrimination power was achieved by *pfs230* with 18 alleles, followed by *pfg377* with 15 alleles. When assays were performed in parallel on RNA and DNA, 85.7% of all *pfs230* samples and 59.5% of all *pfg377* samples contained at least one matching genotype in DNA and RNA.

**Conclusions.** The imperfect detection in both, DNA and RNA, was identified as major limitation for investigating transmission dynamics, owing primarily to the volume of blood processed and the incomplete representation of all clones in the sample tested. Abundant low-density gametocyte carriers impede clone detectability, which may be improved by analyzing larger volumes and detecting initially sequestered gametocyte clones in follow-up samples.

**Keywords.** *Plasmodium falciparum*; transmission dynamics; gametocytes; genotyping; capillary electrophoresis; *pfg377*; *pfs230*.

Malaria infection and transmission dynamics both describe the appearance, loss or persistence of genotypes of *Plasmodium* parasites in a given host. Although infection dynamics describe longitudinal changes among asexual parasite clones, the focus of transmission dynamics lies on the sexual stages, gametocytes. To answer gaps in our knowledge on parasite reproduction and transmission, both the sexual and asexual

stages, concurrently present in a host, need to be analyzed by genotyping. Examples of specific research questions are: Do all concurrent *P. falciparum* clones contribute to gametocyte production? Do drug-resistant clones contribute more to transmission? Does within-host competition between clones or other environmental factors affect the start and duration of gametocyte production?

Superinfections of already infected hosts and a high number of concurrent infections are common in areas of high malaria transmission. Polymorphic molecular markers are amplified to differentiate concurrent clones. The number of clones per blood sample (multiplicity) varies according to the transmission intensity; mean multiplicity of infection (MOI) was 2 in Papua New Guinea (PNG) and almost twice as much in Tanzania [1]. MOI is age-dependent and peaks in highly endemic settings in the age range of 5–9 year-olds [2].

Received 4 January 2014; accepted 28 March 2014; electronically published 25 April 2014.

Information presented in part as a poster: BioMed Central's 2nd Malaria Conference Challenges in Malaria Research: Progress Towards Elimination", Basel, Switzerland, 10–12 October 2012.

Correspondence: Ingrid Felger, PhD, Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland ([ingrid.felger@unibas.ch](mailto:ingrid.felger@unibas.ch)).

**The Journal of Infectious Diseases** 2014;210:1188–97

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

DOI: 10.1093/infdis/jiu236

Human and rodent models suggested that clone multiplicity affects transmission stages [3–5]. Antimalarials also were found to affect transmission. Residual submicroscopic parasitemia after ACT treatment was associated with a higher transmission in Kenyan children [4], but the individual clones within the infection were not differentiated in this study. A further determinant of transmission is the quantity and duration of gametocyte production. Asexual *P. falciparum* clones can persist in a host for many months as asymptomatic infections [6]. From this observation the question arises whether gametocytes are produced continuously by each clone, and whether gametocyte production is up-regulated or suppressed by concurrent clones of the same or other *Plasmodium* species.

Genotyping of gametocytes depends on high stage-specific expression and high genetic diversity of the chosen genotyping marker in the study area. Classical length-polymorphic markers for differentiation of gametocytes are *pfs230* and *pfg377*. *Pfs230* was first observed as a potential transmission-blocking antigen in 1988 and thereafter characterized by several immunological studies [7–10]. Williamson and co-workers first described 2 polymorphic repeat regions in *pfs230* by comparing 5 cultured parasite lines [11]. A separate polymorphic, glutamate-rich region within *pfs230* was described, but diversity was limited [12].

Another frequently used genotyping marker, *pfg377*, is specifically expressed in female gametocytes. Transcripts are detectable from gametocyte stage III onward [13]. Menegon and co-workers developed 4 *pfg377* gametocyte genotyping assays [14]. The first longitudinal monitoring of gametocyte-producing clones was conducted in samples from Sudan. Results indicated that gametocytes were present for up to 8 months of dry season and thus were considered the most probable source of malaria outbreaks in the following rainy season [5, 15]. Gametocytes from multiclonal *P. falciparum* infections persisted 3 times longer than those from single-clone infections; thus multiplicity of infection may promote either longer persistence or continuous production of gametocytes [5]. Feeding experiments in the Gambia confirmed that gametocytes from coinfecting clones were simultaneously transmitted to mosquitoes [16]. Despite a lower multiplicity of gametocyte clones compared to asexual MOI, it was found that clones not detected on RNA level still produced gametocytes and nevertheless contributed to transmission [16]. Of all asexual clones detected in Thai patients, 25% had no corresponding *pfg377* transcript and thus no molecularly detectable level of gametocytes [17].

These previous studies have provided relevant information on malaria epidemiology and transmission dynamics but were hampered by the limited resolution of the available gametocyte-genotyping methods. Size-polymorphic diversity of molecular markers used in these earlier studies was maximal 7 for *pfg377* and 4 for *pfs230* [12, 16]. To improve the discriminatory power of markers *pfg377* and *pfs230*, we created amplicons spanning several polymorphic domains of these genes and

increased accuracy of fragment sizing by replacing gel-based sizing by capillary electrophoresis (CE). In addition, we screened the gametocyte transcriptome [18] for tandem repeat-containing genes expressed only in gametocytes and evaluated these in search for novel high-resolution markers. Our assays were applied to asexual parasites by targeting genomic DNA (gDNA) from field samples and in parallel to gametocytes from the same blood samples by targeting RNA. Our aim was to employ high-resolution typing to gain a clearer picture on how many coinfecting asexual clones simultaneously produce gametocytes.

## METHODS

### Study Population and Ethics

The diversity of genotyping markers was determined in 111 archived anonymized DNA samples collected in Madang province, PNG, from April 2004 to February 2005 [19]. Scientific approval and ethical clearance was obtained from the Medical Research and Advisory Committee of the Ministry of Health in PNG (MRAC no. 09.24). Informed consent was obtained from parents or legal guardians prior to sampling. In addition, 46 archived anonymous RNA samples collected in the course of a cluster-randomized trial in Saponé, Burkina Faso [NCT01256658] [20] were used for evaluation of gametocyte detection assays. Ethical clearance was obtained from the National Ethical Committee for Health Research of Burkina Faso (no. 2013-3-019).

### Nucleic Acid Extraction

DNA samples from PNG, stored at  $-20^{\circ}\text{C}$ , had been extracted previously using QIAamp DNA Blood Kit (Qiagen) [19]. Total RNA of Burkina Faso samples was extracted from 25  $\mu\text{L}$  whole blood stored with 125  $\mu\text{L}$  RNeasy Protect Cell reagent (Qiagen). RNeasy Plus 96 kit (Qiagen) was used as previously described [21]. RNA was eluted in 50  $\mu\text{L}$  water. The gDNA was eluted simultaneously from the gDNA elimination column (provided by the kit) using the QIAamp 96 Blood DNA Kit (Qiagen) protocol from the column washing step onwards. The gDNA was eluted twice in 50  $\mu\text{L}$  of  $40^{\circ}\text{C}$  prewarmed AE elution buffer (Qiagen) following 30 minutes incubation. RNA and gDNA samples were stored at  $-20^{\circ}\text{C}$ .

### Validation of Genotyping Assays and Determination of Allelic Diversity of Markers

Diversity of 6 genotyping markers was determined in 111 gDNA samples from PNG. Primer sequences for *pfg377* (PF3D7\_1250100), *pfs230* (PF3D7\_0209000), *pf11.1* (PF3D7\_1038400), *PF11\_0214* (PF3D7\_1120700), *PF11210w* (PF3D7\_0924600), and *PFL0545w* (PF3D7\_1211000) are given in Table 1. Composition of reaction mixes and thermo profiles are shown in Supplementary Table 1. For CE sizing the

**Table 1. Primary and Nested Primer Sequences for Gametocyte Genotyping Markers**

Marker	Primer	Sequences (5'→3')
<i>Pfs230</i>		
Primary	Pfs230_PF	AAG ACA TGT CGC CCA GGG ATA
	Pfs230_PR	TTC TTC TTC ATC ACC AAA TGG ATA T
Nested	Pfs230_NF	<b>VIC</b> - CAG GGA TAA TTT TGT AAT RGA TGA TG <sup>a</sup>
	Pfs230_NR	ACC TTG CCT TTC TTT TTC ATC TAC A - tail
<i>Pfg377</i>		
Primary	Pfg377_PF	CAC AAC GAA GGT TAT ATA CCT CAT AC
	Pfg377_PR	TCC ATT CTT CTT TAA GGT TCG CTT C
Nested	Pfg377_NF	<b>6FAM</b> - GAA GAT GAC GAA GGG GAT GAA G
	Pfg377_NR	CTG TAA GAA TTG GTT ATT ACT TTT GTG G - tail
<i>PF11.1</i>		
Primary	Pf11.1_PF1 <sup>b</sup>	GAT ATA TTC TAA TAA T TG TTC CAA TGG
	Pf11.1_PF2	AAG TGC AGG GGA TAG TGC AG
	Pf11.1_PR	CGG TAA TAC CAT AAG CTC CTC CT
Nested	Pf11.1_NF	<b>6FAM</b> - GGA ATA AGG ATG ATG ATG ACG AA
	Pf11.1_NR	AAC CTT CAA ATT CTT TGT CTC TTT C - tail
<i>PF11_0214</i>		
Primary	PF11_0214_PF	TCG AGA CAA ATT GAA AAG TTA TGG
	PF11_0214_PR	TTA GTG GAT AAA TGA ATA TCT ACC G
Nested	PF11_0214_NF	<b>6FAM</b> - AAT GAT ACA GAT TGT GAA GAA TGG T
	PF11_0214_NR	TGA GGA ATA TCG TTT TGT ATA AAT GTT - tail
<i>PF11210w</i>		
Primary	PF11210w_PF	TTG ATA AGG GAT ATA TAC ACA ACC ATA
	PF11210w_PR	TTC CCG TTG TGT ATT TAA GTA GAA T
Nested	PF11210w_NF	<b>6FAM</b> - TGT TTC AAT TTA CCA TCT TTC TTT TC
	PF11210w_NR	GTT TTT CAA TTT TTA TGT TGT TCT CCA - tail
<i>PFL0545w</i>		
Primary	PFL0545w_PF	GGA AGG AAA CGA AGA AGA AAC A
	PFL0545w_PR	AAA GAT TGA AAT GGA GAT TCA CCT
Nested	PFL0545w_NF	<b>VIC</b> - TGA CAA AGG GCA CTT TAT TAT TT
	PFL0545w_NR	TTT CTT CAA CAG CAT TTT GCA T - tail

<sup>a</sup> Primer sequence contains a wobble: R = A/G.

<sup>b</sup> Pf11.1\_PF1 is spanning an intron boundary indicated by “|”.

products were diluted in water according to their agarose gel band intensity. Samples were analyzed by ABI3130xl using GS500LIZ as size standard. Electropherograms were analyzed using GeneMapper Software version 3.7. A cutoff set at 250 fluorescence units (FU) defined the minimal required peak height. In samples containing dominant peaks of >10 000 FU, the cutoff was increased to 500 FU. Stutter peaks (defined by accompanying peaks with a regular pattern of >6 bp and heights <20% of the main peak) were censored. A bin width of 3 bp was defined for each allele to accommodate small variations in fragment sizing. To test whether a size standard containing larger fragments would provide more accurate CE sizing, a subset of 13 *pfg377* fragments were simultaneously sized by CE using GS1200LIZ (Applied Biosystems). The expected heterozygosity ( $H_E$ ) was calculated as published elsewhere [22].

### Sequencing of PCR Fragments of Single Clone Infections for Evaluating Fragment Sizing

Nucleotide sequences of 12 *pfg377* and 10 *pfs230* nested polymerase chain reaction (nPCR) fragments from single clone infections were determined in both directions for *pfg377* and in one direction for *pfs230* by direct Sanger sequencing. Sequences were analyzed with BioEdit version 7.3.2, and alignments were performed with T-Coffee multiple alignment server and Box-Shade server version 3.21. Sequences were submitted to GenBank [KJ566743-KJ566764].

### Evaluation of Sensitivity of Reverse Transcription (RT)-PCR

The detection limits of all nested RT-PCR assays were evaluated on a trendline of stage IV/V gametocyte in vitro culture of *P. falciparum* 3D7 as previously described [21]. RT of

gene-specific complementary DNA (cDNA) was performed in a multiplex reaction using *pfg377* and *pfs230* primary reverse primers, 15  $\mu$ L RNA and Superscript II (Invitrogen) according to the manufacturer's protocol. In a second multiplex RT reaction cDNA was reverse transcribed for *pf11.1*, *PF10\_0214*, *PF11210w*, and *PFL0545w* using the primary reverse primers (Table 1). In total, 4  $\mu$ L of cDNA were added to the primary PCR (pPCR) mix and 2  $\mu$ L of primary product to nPCR. The composition of reaction mixes and thermo profiles are shown in [Supplementary Table 1](#). The nPCR products were run on a 2% agarose gel. The detection limit of each marker was compared to that of *pfs25* qRT-PCR, which is highly sensitive and widely used [21].

### Effects of DNase Treatment on RNA Quality

For marker *pf11.1* an additional forward PCR primer was designed to span an exon-intron boundary (Table 1). Including this primer-binding site into an amplicon covering the polymorphic region of *pf11.1* resulted in a 680 bp longer fragment. The sensitivity of both *pf11.1* assays was assessed with 2 gametocyte trendlines that differed by omitting the DNase digest for the intron-spanning assay [21]. Assay conditions were identical except for a higher annealing temperature (58°C) for pPCR with the intron-spanning primer.

### Evaluation of Gametocyte Genotyping Markers in Field Samples

The discrimination power for gametocyte clones in field samples was assessed for the 2 most diverse markers using 46 RNAs from Burkina Faso. Alleles detected on RNA level were compared to those found in gDNA of the same sample. In total, 5  $\mu$ L RNA, equivalent to 2.5  $\mu$ L whole blood, were reverse-transcribed and amplified for *pfs230* and *pfg377* by AffinityScript One-Step RT-PCR kit (Agilent Technologies) in simplex reactions. The nPCR was performed using 1  $\mu$ L of primary product. Composition of reaction mixes and thermo profiles are shown in [Supplementary Table 1](#). Reaction conditions were modified because the SuperScript II protocol (Invitrogen) used for work on parasite culture performed less well in field samples (data not shown).

The gDNA coextracted from the same blood samples was amplified for *pfg377* and *pfs230* as described above with the following modifications: an increased amount of 5  $\mu$ L gDNA, equivalent to 1.25  $\mu$ L whole blood, was added into a 30  $\mu$ L reaction. Numbers of gametocytes originally present in whole blood samples were calculated by a conversion factor of  $10^{-1.6225} \times (\text{copy number } pfs25 \text{ transcripts}/\mu\text{L whole blood})^{0.8518}$  as described elsewhere [21]. Correlation between gametocyte density (*pfs25* transcripts) and asexual density (S-type *18SrRNA* copy numbers) with DNA or RNA-derived MOI was analyzed by Kendall rank correlation  $\tau$  for nonparametric data.

## RESULTS

### High Allelic Diversity of Gametocyte Genotyping Markers in PNG

New length polymorphic and gametocyte specifically expressed genes were selected by screening publically available gametocyte transcriptome data [18] followed by tandem repeat detection using Tandem Repeats Finder [23]. Primers were designed to maximize size variation in amplified fragments. For *pfg377* we combined polymorphic regions 2 and 3 described by Menegon into one larger amplicon [14]. Similarly, also our *pfs230* amplicon spans 2 polymorphic regions (Figure 1A). Diversity of both markers in 111 gDNAs from PNG was highest with 18 *pfs230* alleles ( $H_E = 0.92$ ) and 15 *pfg377* alleles ( $H_E = 0.81$ ). The detection limit of each assay and parameters describing the genetic diversity and resolution of each marker are listed in Table 2. Allelic frequencies of the 6 gametocyte markers showed equal distribution for most of the *pfs230* alleles, but for *pfg377* a predominant allele (39%; Figure 1B). Sequence alignments of 12 *pfg377* and 10 *pfs230* nPCR products ([Supplementary Figure 1](#)) served for validating CE fragment sizing. Sizing of *pfs230* fragments was more accurate than that of the larger *pfg377* fragments. Comparison of 38 amplicons sized in parallel with GS500LIZ and GS1200LIZ size standards indicated that GS1200LIZ yielded better resolution for *pfg377* with amplicon sizes >700 bp ([Supplementary Figure 2](#)). GS500LIZ worked well for *pfs230* with amplicons <600 bp.

### Detection Limits of Gametocyte Assays Assessed With a Trendline of Cultured Gametocytes

The limit of detection (LOD) of our gametocyte typing assays ranged from 1 (*pfg377* and *pf11.1* without DNase digestion) to 5 (*pf11.1* with DNase digestion) and 10 gametocytes/ $\mu$ L culture (*pfs230*, *PF11\_0214*, *PF11210w* and *PFL0545w*; Table 2). These LODs were 50–500 times less sensitive than that of *pfs25*, a qRT-PCR assay able to detect 0.02 gametocytes/ $\mu$ L blood [21, 24]. Our *pfg377* LOD was in line with earlier reports [14].

### Quantifying the Gain in Sensitivity After Bypassing DNase Digestion

Using an intron-spanning marker permits omitting DNase digestion prior to reverse transcription but also increases amplicon length. By using alternative primers for marker *pf11.1* we analyzed whether bypassing digestion would exceed the benefit of a smaller amplicon. Sensitivity was 5-fold higher for the 680 bp longer fragment not requiring DNase digestion (Table 2).

### Evaluation of Gametocyte Typing Markers in Field Samples

Markers *pfs230* and *pfg377* were genotyped in parallel in paired DNA/RNA samples coextracted from 46 blood samples from Burkina Faso, all of which had been gametocyte-positive by *pfs25* qRT-PCR. RT-PCR was successful in 42/46 field samples



**Table 2. Resolution of 6 Polymorphic Gametocyte Markers in Comparison to Asexual Marker *Msp2* in 111 *P. falciparum* Positive Cross-Sectional Samples From PNG**

Marker	Positive Samples	No. of Clones	No. of Alleles	CE-Product Size Range	Mean MOI	$H_E$	In Vitro Detection Limit (Gametocyte/ $\mu$ L 3D7 Culture)
<i>Msp2</i> <sup>a</sup>	111/111	...	...	...	1.56	...	...
<i>Pfs230</i>	95/111	124	18	463–614	1.31	0.923	10
<i>Pfg377</i>	97/111	117	15	521–695	1.21	0.816	1
<i>Pf11.1</i>	100/111	125	10	143–327	1.25	0.734	1 if intron boundary 5 if no intron boundary
<i>PF11_0214</i>	100/111	104	4	355–376	1.04	0.293	10
<i>PFI1210w</i>	90/111	110	5	442–551	1.22	0.527	10
<i>PFL0545w</i>	95/111	113	7	453–519	1.19	0.546	10


Abbreviations:  $H_E$ , heterozygosity; MOI, multiplicity of infection; *Msp2*, merozoite surface protein 2.

<sup>a</sup> Results from [19].

gametocytes from multiclone infections. Multiple *P. falciparum* infections can coexist over weeks or months, but the variation in their relative densities and contribution to transmission over time has not yet been adequately quantified. The available data on gametocytes production of individual co-infecting clones were compromised by limited size-polymorphism in marker *pfg377*-R3 [5, 15–17, 25]. High-endemic settings are characterized by high MOI, where a limited marker resolution of  $\geq 7$  alleles will not adequately discriminate gametocytes of all clones present in a

sample. By combining 2 repeat regions into 1 amplicon, we substantially improved the discriminatory power of both major markers. In 46 samples from Burkina Faso we detected 19 *pfg377* and 18 *pfs230* alleles by CE. A comparable diversity was observed in samples from PNG indicating that these markers may have sufficiently high diversity for genotyping in both African and non-African populations with different transmission intensity.

High MOI in the Burkina Faso study area [26] can contribute to discrepant results between RNA- and DNA-derived MOI.



**Figure 2.** Schematic of analytical procedures (right panel) and overlap of genotypes detected simultaneously in RNA and DNA by blood sample (left panel). A, *Pfs230*, 42 paired RNA/DNA samples. B, *Pfg377*, 37 paired RNA/DNA samples. Abbreviation: MOI, multiplicity of infection.

**Table 3. Discrimination Power and Test Sensitivity of Gametocyte Typing Markers *pfs230* and *pfg377* in 46 Blood Samples From Burkina Faso**

Marker	<i>pfs230</i>	<i>pfg377</i>
No. of successful amplified samples	42/46	37/46
Detection limit in field samples <sup>a</sup>	2 gametocyte/ $\mu$ L WB	3.5 gametocyte/ $\mu$ L WB
Median gametocyte count <sup>a</sup>	17.0 gametocyte/ $\mu$ L WB	17.9 gametocyte/ $\mu$ L WB
No. of different alleles	18	19
DNA/RNA sample pairs with at least 1 matching PCR fragment	38/42 (85.7%)	22/37 (59.5%)
Total no. of PCR fragments detected (DNA and RNA combined)	132	114
Proportion of DNA fragments not found on RNA level	41/93 (44.1%)	48/78 (61.5%)
Proportion of RNA fragments not found on DNA level	39/91 (42.9%)	36/66 (54.5%)
Combined mean MOI (DNA and RNA)	3.14 [range 1–6]	3.08 [range 1–5]
Mean MOI (DNA)	2.21 [range 1–5]	2.11 [range 1–4]
Mean MOI (RNA)	2.17 [range 1–5]	1.78 [range 1–4]

Abbreviations: MOI, Multiplicity of infection; PCR, polymerase chain reaction; WB, whole blood.

<sup>a</sup> Determined by a conversion factor based on *pfs25* transcripts copies/ $\mu$ L RNA [21].

High MOI implies high clone competition in the host, resulting in turn in fluctuations in clone densities [27]. During PCR the presence of several templates of various concentrations may lead to template competition. Both effects of high MOI result in imperfect detectability [28]. This effect of competing templates, leading to lack of detection of genotypes either in DNA- or RNA-based detection, is enhanced by applying a cut-off for peak height in CE to separate background noise from real signals (Figure 3). In view of these inherent shortfalls, it seems essential to optimize sampling and preservation of both DNA and RNA to maximize the volume of template in PCR and RT-PCR in order to minimize the failures to detect all alleles present.

When comparing paired RNA- and DNA-derived fragments, 3 scenarios are expected: (I) RNA- and DNA-derived alleles match; here asexual stages and gametocytes of a clone are concurrently present in the blood sample, or DNA- and RNA- alleles both derive from gametocytes only. Yet, in multiclonal infections a perfect match might be rare because the ratio of asexual vs sexual stages of each clone could differ considerably. (II) DNA-derived alleles exceed those obtained from RNA of the same sample. This is intuitively expected, because only some of the concurrent clones might produce gametocytes, as suggested by the frequent absence of gametocytes in some of

the *P. falciparum*-positive blood samples despite molecular detection. (III) RNA-derived alleles are detected despite their absence on DNA level. This could occur when a gametocyte clone is still circulating while its asexual stages are already cleared by the immune system or below the detection limit. The gametocytes' nuclear DNA in this scenario remains below the detection limit of PCR or suffers from competition in multiclonal infections.


In our study all 3 scenarios were seen, with scenario I predominant for *pfs230* and scenario II for *pfg377*. An explanation for this discrepancy is offered by the differential performance of our 2 markers, which differed in their ability to detect a clone on both DNA- plus RNA level: *pfs230* detected at least one matching genotype in >80% of samples, in contrast to only 60% for *pfg377*. Similarly, more RNA clones were missed by *pfg377* (60%) than by *pfs230* (45%). This argues for a higher sensitivity of *pfs230* compared to *pfg377* RT-PCR.

The imperfect detectability observed in asexual clones [6, 28] is aggravated in gametocyte detection, because gametocytes occur in densities about 100-fold lower than asexual stages [29]. Detection of gametocytes depends greatly on the blood volume processed, whereby a rare gametocyte clone might be present or absent by chance in the limited volume of blood processed. An additional limitation specific for *Pfg377* consists in its expression restricted to female gametocytes. Our RT-PCR assays amplified gametocyte-specific transcripts in field samples that contained as little as 2 gametocytes/ $\mu$ L whole blood, as indicated by the LOD for *pfs230* and is thus in the range of previously published assays [14, 30]. Even though this LOD permits detection of submicroscopic gametocytes, it does not reach the up to 100-fold higher sensitivity of *pfs25* qRT-PCR [21]. This difference is mainly due to a lower expression rate of *pfs230* compared to *pfs25*. Amplicon size and differential stability of the RNA may play an additional role as previously suggested [21].


We propose another strategy to address the problem of imperfect detectability of gametocyte clones: a longitudinal study design would permit to detect a particular genotype on RNA-level in a subsequent blood samples harboring higher gametocyte density. It is possible that sexual and asexual densities do not peak at the same time due to a 10 days maturation period of gametocytes. Therefore, a better match may be achieved by comparing results from consecutive bleeds. A gametocyte clone missed at an earlier sampling date might appear in the following sample. This approach parallels our strategy adapted to track asexual clones also fluctuating in their densities over time [28, 31, 32]. Nevertheless, even a longitudinal approach to gametocyte tracking will not overcome the imperfect detection of a gametocytemia that is persistently very low.

No other candidate of higher diversity and sensitivity than our CE-based *pfg377* and *pfs230* assays was found. Thus, length polymorphism of intragenic repeat regions in gametocyte-expressed genes seems to be less extensive than in genes

### Example 1 – *pfg377*



### Example 2 – *pfg377*



**Figure 3.** Electropherograms of *pfg377* fragments amplified by nested PCR from gDNA and nested RT-PCR from RNA coextracted from the same sample. Arrows indicate minority peaks, which had fallen below the cutoff, whereas matching fragments of significant peak height were present in the corresponding sample. Abbreviation: RT-PCR, reverse transcription polymerase chain reaction.

expressed in asexual stages. For improving discrimination power beyond 18 alleles by *pfs23*-CE, alternative approaches could be investigated in, for example, future detection of single nucleotide polymorphisms by targeted next generation sequencing. However, the major challenges will likely persist, e.g. imperfect clone detectability in a limited blood volume from the field, expression levels of polymorphic gametocyte-specific genes, and assay sensitivity impaired by long amplicons.

A major gap in our knowledge of *P. falciparum* transmission dynamics is the onset and duration of gametocytogenesis of each asexual clone in relation to coinfecting clones and the contribution of resistant clones to transmission. We envisage that the molecular description of clone transmission dynamics

may yield molecular gametocyte-specific parameters similar to those used in the description of infection dynamics and complementing these, for example, the duration of gametocyte production or multiplicity of gametocyte clones. This will open up new investigations of clone interaction, within-host competition, and clonal fitness. So far, very little is known on gametocyte dynamics in natural infections, where concurrent clonal infections might contribute to transmission equally or in competition with each other. This determines parasite recombination in mosquitoes, which in turn has major consequences for development of multilocus drug resistance phenotypes or antigenic diversity.

In summary, we improved the resolution of existing markers for discriminating gametocyte clones, but were unable to find



alternative polymorphic markers of higher diversity. *Pfs230* emerged as the most sensitive and diverse marker. Detectability of minority clones was identified as a major problem for matching asexual clones with their gametocytes. The loss of minority clones seemed strongest in the high transmission setting with high mean MOI where about half of all clones were missed in either of the paired samples. Longitudinal analyses are needed to permit temporally staggered alignment of fragments to compensate imperfect detectability. This calls for longitudinal studies with short-term sampling intervals specifically designed for genotyping DNA and RNA targets in parallel.

## Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online (<http://jid.oxfordjournals.org/>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

## Notes

**Acknowledgments.** We thank the study participants and their parents or guardians, and the field teams in PNG and Burkina Faso.

**Author contribution.** R. W. and I. F. designed and performed research and wrote the article; I. S., A. B. T., and P. S. contributed field samples, L. T., H. P. B., and I. M. contributed new reagents or analytical tools.

**Financial support.** This work was supported by Swiss National Science Foundation [grant 310030\_134889], International Centers of Excellence in Malaria Research [grant U19 AI089686], National Health and Medical Research Council [grants GNT1021544 and GNT1043345] and Bill and Melinda Gates Foundation [grant OPP1034577].

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- Schoepflin S, Valsangiacomo F, Lin E, Kiniboro B, Mueller I, Felger I. Comparison of *Plasmodium falciparum* allelic frequency distribution in different endemic settings by high-resolution genotyping. *Malar J* **2009**; 8:250.
- Smith T, Beck H-P, Kitua A, et al. Age dependence of the multiplicity of *Plasmodium falciparum* infections and of other malariological indices in an area of high endemicity. *Trans R Soc Trop Med Hyg* **1999**; 93 (suppl 1):15–20.
- Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. *Proc Natl Acad Sci U S A* **2007**; 104:19914–9.
- Beshir KB, Sutherland CJ, Sawa P, et al. Residual *Plasmodium falciparum* parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. *J Infect Dis* **2013**; 208:2017–24.
- Nassir E, Abdel-Muhsin AM, Suliaman S, et al. Impact of genetic complexity on longevity and gametocytogenesis of *Plasmodium falciparum* during the dry and transmission-free season of eastern Sudan. *Int J Parasitol* **2005**; 35:49–55.
- Felger I, Maire M, Bretscher MT, et al. The dynamics of natural *Plasmodium falciparum* infections. *PLoS ONE* **2012**; 7:e45542.
- Kaslow DC, Quakyi IA, Syn C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. *Nature* **1988**; 333:74–6.
- Eksi S, Czesny B, Van Gemert GJ, Sauerwein RW, Eling W, Williamson KC. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. *Mol Microbiol* **2006**; 61:991–8.
- Williamson KC, Keister DB, Muratova O, Kaslow DC. Recombinant Pfs230, a *Plasmodium falciparum* gametocyte protein, induces antisera that reduce the infectivity of *Plasmodium falciparum* to mosquitoes. *Mol Biochem Parasitol* **1995**; 75:33–42.
- Pradel G. Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies. *Parasitology* **2007**; 134(Pt. 14):1911–29.
- Williamson KC, Kaslow DC. Strain polymorphism of *Plasmodium falciparum* transmission-blocking target antigen Pfs230. *Mol Biochem Parasitol* **1993**; 62:125–7.
- Niederwieser I, Felger I, Beck HP. Limited polymorphism in *Plasmodium falciparum* sexual-stage antigens. *Am J Trop Med Hyg* **2001**; 64:9–11.
- Alano P, Read D, Bruce M, et al. COS cell expression cloning of Pfg377, a *Plasmodium falciparum* gametocyte antigen associated with osmiophilic bodies. *Mol Biochem Parasitol* **1995**; 74:143–56.
- Menegon M, Severini C, Sannella A, et al. Genotyping of *Plasmodium falciparum* gametocytes by reverse transcriptase polymerase chain reaction. *Mol Biochem Parasitol* **2000**; 111:153–61.
- Abdel-Wahab A, Abdel-Muhsin AM, Ali E, et al. Dynamics of gametocytes among *Plasmodium falciparum* clones in natural infections in an area of highly seasonal transmission. *J Infect Dis* **2002**; 185:1838–42.
- Nwakanma D, Kheir A, Sowa M, et al. High gametocyte complexity and mosquito infectivity of *Plasmodium falciparum* in the Gambia. *Int J Parasitol* **2008**; 38:219–27.
- Nakazawa S, Culleton R, Maeno Y. In vivo and in vitro gametocyte production of *Plasmodium falciparum* isolates from Northern Thailand. *Int J Parasitol* **2011**; 41:317–23.
- Young JA, Fivelman QL, Blair PL, et al. The *Plasmodium falciparum* sexual development transcriptome: a microarray analysis using ontology-based pattern identification. *Mol Biochem Parasitol* **2005**; 143:67–79.
- Marfurt J, Mueller I, Sie A, et al. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against *Plasmodium falciparum* and *P. vivax* malaria in Papua New Guinea. *Am J Trop Med Hyg* **2007**; 77:947–54.
- Tiono AB, Ouedraogo A, Ogutu B, et al. A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of *Plasmodium falciparum* in Burkina Faso. *Malar J* **2013**; 12:79.
- Wampfler R, Mwingira F, Javati S, et al. Strategies for detection of *Plasmodium* species gametocytes. *PLoS ONE* **2013**; 8:e76316.
- Koepfli C, Ross A, Kiniboro B, et al. Multiplicity and diversity of *Plasmodium vivax* infections in a highly endemic region in Papua New Guinea. *PLoS Negl Trop Dis* **2011**; 5:e1424.
- Benson G. Tandem repeats finder: a program to analyze DNA sequences. *Nucleic Acids Res* **1999**; 27:573–80.
- Schneider P, Schoone G, Schallig H, et al. Quantification of *Plasmodium falciparum* gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. *Mol Biochem Parasitol* **2004**; 137:35–41.
- Gatei W, Kariuki S, Hawley W, et al. Effects of transmission reduction by insecticide-treated bed nets (ITNs) on parasite genetics population structure: I. The genetic diversity of *Plasmodium falciparum* parasites by microsatellite markers in western Kenya. *Malar J* **2010**; 9:353.
- Soulama I, Nebie I, Ouedraogo A, et al. *Plasmodium falciparum* genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso. *Malar J* **2009**; 8:135.

27. Henning L, Schellenberg D, Smith T, et al. A prospective study of *Plasmodium falciparum* multiplicity of infection and morbidity in Tanzanian children. *Trans R Soc Trop Med Hyg* **2004**; 98:687–94.
28. Koepfli C, Schoepflin S, Bretscher M, et al. How much remains undetected? Probability of molecular detection of human *Plasmodia* in the field. *PLoS ONE* **2011**; 6:e19010.
29. Ouedraogo AL, Bousema T, de Vlas SJ, et al. The plasticity of *Plasmodium falciparum* gametocytaemia in relation to age in Burkina Faso. *Malar J* **2010**; 9:281.
30. Maeno Y, Nakazawa S, Dao LD, et al. A dried blood sample on filter paper is suitable for detecting *Plasmodium falciparum* gametocytes by reverse transcription polymerase chain reaction. *Acta Trop* **2008**; 107:121–7.
31. Sama W, Owusu-Agyei S, Felger I, Vounatsou P, Smith T. An immigration-death model to estimate the duration of malaria infection when detectability of the parasite is imperfect. *Stat Med* **2005**; 24:3269–88.
32. Bretscher MT, Valsangiacomo F, Owusu-Agyei S, Penny MA, Felger I, Smith T. Detectability of *Plasmodium falciparum* clones. *Malar J* **2010**; 9:234.